StockTipsArenaBeta

BUY IPCA Laboratories Limited — Emkay Global

BUYIPCA Laboratories Limited

byEmkay GlobalHorizon: NA (inferred 1 year)2 Jun 2026via Institutional / Brokerage Research

Entry₹1,507.7Inferred
Target₹1,800
Total upside +19.39% (call closed)
Stop lossNot given
Exit₹1,8006 Jul 2026, 12:00 am
Target hit+19.39%0.00%upside left
Follow Emkay Global for new calls(65% target hit, 397 closed calls)Get alertsWatch IPCALAB for new buy/sell callsGet alertsSee 2 active Long-term calls on IPCALABSee 40 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 9:48 pm IST
4 supporting1 neutral0 opposing
Supports the BUY call (4)

IPCA Laboratories Limited's Board approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. The merger aims for operational synergies, cost optimization,

NSE · Outcome of Board Meeting·26 Jun · 1w ago

(opens in new tab)

IPCA Laboratories has entered a licensing agreement to access a proprietary biologics delivery platform for developing oncology and inflammatory disease treatments.

NSE · Press Release·12 Jun · 3w ago

(opens in new tab)

Ipca Laboratories has entered into a global licensing agreement with Bhami's Research Laboratory (BRL) for BRL's proprietary high-concentration subcutaneous biologics delivery platform. This collabora

BSE · Company Update·12 Jun · 3w ago

(opens in new tab)

2 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·2 Jun · 1mo ago

Neutral / worth noting (1)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.